Finally, since it appeared to limit CPT-driven inflammation from both canonical and non-canonical STING signaling, without promoting cancer cell proliferation, we also tested the effect of ERK1/2 inhibition with SCH772984 on CPT-treated PC-3, SK-OV-3 and BT-549 cells (Figure 4F). This evidence concerns the gene MAPK3 and cancer.